Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Meitheal Pharmaceuticals, Inc.

News headline image
Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan) Injection
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Receives Approval from the US Food and Drug Administration for CONTEPO™ (fosfomycin) for injection in Patients ≥ 18 Years Having Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP)
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Appointment of Dr. Keith Robinson as Chief Medical Officer and Expansion of Medical Affairs Operation
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Approval and Launch of Liraglutide Injection in the United States
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for XENLETA® (lefamulin acetate)
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S.
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Joins Biosimilars Forum
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
News headline image
Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Anticoagulant Treatment of COVID-19 Patients
From Meitheal Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.